More on reports of esophageal cancer with oral bisphosphonate use

N Engl J Med. 2009 Apr 23;360(17):1789-90; author reply 1791-2.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Letter

MeSH terms

  • Administration, Oral
  • Bone Density Conservation Agents / adverse effects*
  • Bone Density Conservation Agents / therapeutic use
  • Calcitonin / therapeutic use
  • Diphosphonates / adverse effects*
  • Esophageal Neoplasms / chemically induced
  • Esophageal Neoplasms / epidemiology*
  • Humans
  • Incidence
  • Osteoporosis / drug therapy
  • Raloxifene Hydrochloride / therapeutic use
  • SEER Program
  • United States / epidemiology

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Raloxifene Hydrochloride
  • Calcitonin